Identification of patients with Graves’ disease who benefit from high-dose radioactive iodine therapy Shiro WatanabeShozo OkamotoKohsuke Kudo Original Article 16 August 2022 Pages: 923 - 930
PD1 blockade alters cell-cycle distribution and affects 3′-deoxy-3′-[18F]fluorothymidine uptake in a mouse CT26 tumor model Motofumi SuzukiTakuma MatsudaMikako Ogawa Original Article 15 August 2022 Pages: 931 - 940
New index to assess the extent of bone disease in patients with prostate cancer using SPECT/CT Hajime IchikawaTakayuki ShibutaniYuki Taniguchi Original Article 01 September 2022 Pages: 941 - 950
Semiquantitative analysis using whole-body dynamic F-18 fluoro-2-deoxy-glucose–positron emission tomography to differentiate between benign and malignant lesions Mirei WatanabeHiroki KatoNoriyuki Tomiyama Original Article 03 September 2022 Pages: 951 - 963
Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment Tugba Akin TelliSalih OzguvenPerran Fulden Yumuk Original Article 23 August 2022 Pages: 964 - 975
[99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor Sajad KaihaniNourollah SadeghzadehSeyed Mohammad Abedi Original Article 12 September 2022 Pages: 976 - 985
Methods of calculating 123I-β-methyl-P-iodophenyl-pentadecanoic acid washout rates in triglyceride deposit cardiomyovasculopathy Zhuoqing ChenKenichi NakajimaSeigo Kinuya Original Article Open access 25 September 2022 Pages: 986 - 997
Attenuation correction for phantom tests: an alternative to maximum-likelihood attenuation correction factor-based correction for clinical studies in time-of-flight PET Tetsuro MizutaYoshiyuki YamakawaKazunari Ishii Short Communication 28 September 2022 Pages: 998 - 1006
